Natascha LELEU-CHAVAIN

Dr. Natascha LELEU-CHAVAIN

Institute for Translational Research in Inflammation, Lille, Hauts-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CBChristophe Biot
Christophe Biot
WDWassim Daher
Wassim Daher
NLNatascha LELEU-CHAVAIN
Natascha LELEU-CHAVAIN
TFThierry Fandeur
Thierry Fandeur
JKJamal Khalife
Jamal Khalife
Erik De ClercqErik De Clercq
Erik De Clercq

19 June 2008 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
NLNatascha LELEU-CHAVAIN
Natascha LELEU-CHAVAIN
Hervé VezinHervé Vezin
Hervé Vezin
DDDaniel Dive
Daniel Dive
NTNadia Touati
Nadia Touati
JPJean-François Paul
Jean-François Paul
CBChristophe Biot
Christophe Biot

14 November 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WTWei Tuo
Wei Tuo
NLNatascha LELEU-CHAVAIN
Natascha LELEU-CHAVAIN
John SpencerJohn Spencer
John Spencer
SSSupojjanee Sansook
Supojjanee Sansook
RMRégis Millet
Régis Millet
PCPhilippe Chavatte
Philippe Chavatte

1 September 2010 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NLNatascha LELEU-CHAVAIN
Natascha LELEU-CHAVAIN
CBChristophe Biot
Christophe Biot
The importance of organometallics can be noticed by their presence in all life organisms. The most known natural organometallic molecule is vitamin B12, a porphyrin containing a cobalt atom, useful for several enzymatic transformations. Based on the remarkable properties of this class of compounds, a new area of medicinal research was developed. Gerard Jaouen was the first to introduce the term of “bioorganometallic chemistry” in 1985 although the first organometallic therapeutical was Salvarsan®, discovered by Paul Ehrlich (Nobel Prize in Medicine in 1908). Bioorganometallic chemistry consists of the synthesis and the study of organometallic complexes, complexes with at least one metal-carbon bond, in a biological and medicinal interest. This field of research was accentuated by the discovery of the ferrocene in 1951 by Pauson and Kealy, confirmed in 1952 by Wilkinson (Nobel Prize in 1973). Today, bioorganometallic chemistry includes 5 main domains: (1) organometallic therapeuticals, (2) toxicology and environment, (3) molecular recognition in aqueous phases, (4) enzymes, proteins and peptides, (5) bioanalysis and pharmaceutical sensors. In this review, we focused on organometallic therapeuticals. The exceptional properties of organometallics are first described and then, an overview on the main organometallic complexes used for drug design is presented. This review gives an idea how organometallics can be used for the rational design of new drugs.

1 July 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CBChristophe Biot
Christophe Biot
WDWassim Daher
Wassim Daher
CNCheikh M. Ndiaye
Cheikh M. Ndiaye
PMPatricia Melnyk
Patricia Melnyk
BPBruno Pradines
Bruno Pradines
DDDaniel Dive
Daniel Dive

23 March 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NWNicole I. Wenzel
Nicole I. Wenzel
NLNatascha LELEU-CHAVAIN
Natascha LELEU-CHAVAIN
YWYulin Wang
Yulin Wang
WFWolfgang Friebolin
Wolfgang Friebolin
LMLouis Maes
Louis Maes
EDElisabeth Davioud-Charvet
Elisabeth Davioud-Charvet